No, Zenhale Does Not Have the Same Evidence as Symbicort for SMART/MART
Zenhale (mometasone/formoterol) lacks the clinical trial evidence that supports Symbicort (budesonide/formoterol) for SMART/MART regimens, and the NAEPP guidelines explicitly state that SMART studies were "almost exclusively performed with budesonide/formoterol." 1
The Evidence Gap
What the Guidelines Say
The 2020 NAEPP Expert Panel Report clearly addresses this exact question when discussing whether ICS/LABA combinations other than budesonide/formoterol can be used for SMART 1:
- Studies of SMART were almost exclusively performed with budesonide/formoterol
- While the working group was "careful to designate 'ICS/formoterol' rather than 'budesonide/formoterol,' leaving open the possibility of using other ICSs in combination with formoterol," this is theoretical, not evidence-based
- "Theoretically, other ICSs could be effective as well, but they have not been studied in this manner" 1
The Critical Requirement: Formoterol
The guidelines emphasize that formoterol is essential because it has rapid onset of action, which is necessary for the reliever component of SMART 1. Zenhale does contain formoterol, so it meets this basic requirement. However, having the right LABA is only part of the equation.
The Clinical Trial Evidence
Symbicort's Robust Evidence Base
The evidence supporting SMART with budesonide/formoterol includes:
- Multiple large randomized controlled trials demonstrating 21-43% reductions in severe exacerbations compared to various comparators 2, 3, 4
- Meta-analyses showing significant reductions in severe exacerbations across different comparator groups 3
- Studies specifically demonstrating safety with high-use episodes and cumulative corticosteroid exposure 2
- Real-world evidence confirming efficacy in routine clinical practice 5, 6
Zenhale's Absence from SMART Literature
No published randomized controlled trials have evaluated mometasone/formoterol in a SMART/MART regimen. The systematic reviews and clinical trials supporting SMART recommendations used budesonide/formoterol (Symbicort) or beclometasone/formoterol 7.
Practical Implications
What This Means for Clinical Practice
SMART is currently an off-label use for all ICS/LABA combinations in the United States 1, but the evidence supporting this off-label use exists only for budesonide/formoterol and to a lesser extent beclometasone/formoterol 7.
If insurance only covers mometasone/formoterol (Zenhale), the guidelines suggest 1:
- "One would want to weigh the considerations" about using an unstudied ICS in SMART
- The approach "stands to reason" theoretically but "has never been tested"
- You should ensure patients "clearly understand which inhaler to use as their reliever"
The Safer Approach
When implementing SMART, use budesonide/formoterol (Symbicort) as the first choice 8, 7. This is a SOR B recommendation based on the available evidence 8.
If forced to use mometasone/formoterol due to insurance constraints:
- Recognize you are extrapolating beyond the evidence base
- Provide extra patient education about the regimen
- Monitor closely for efficacy and safety
- Consider advocating for formulary coverage of budesonide/formoterol for SMART indication
Key Caveats
Important Limitations
- The theoretical rationale for using other ICS/formoterol combinations is reasonable—all ICS have anti-inflammatory effects, and formoterol provides rapid bronchodilation
- However, pharmacokinetic differences between ICS molecules (potency, onset, duration, systemic absorption) could affect the risk-benefit profile in a SMART regimen
- The safety profile with frequent as-needed use (up to 12 inhalations daily) has only been established for budesonide/formoterol 2, 7
What We Don't Know About Zenhale in SMART
Without clinical trials, we lack data on:
- Whether mometasone/formoterol reduces exacerbations as effectively as budesonide/formoterol in SMART
- The safety profile with high-use episodes (>8 additional inhalations per day)
- The cumulative systemic corticosteroid exposure compared to traditional regimens
- Patient adherence and real-world effectiveness
Bottom line: While Zenhale contains formoterol and theoretically could work in a SMART regimen, it lacks the clinical trial evidence that supports Symbicort for this indication. Use budesonide/formoterol when implementing SMART unless insurance barriers make this impossible.